Project Grant R21NS135426
- This federal Project Grant award for $481,250.00, awarded on August 1, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the use of potent prion protein (PrP)-lowering reagents to treat prion disease. The key research objectives are to: Quantify the depth of PrP suppression achievable under a repeated dosing regimen....
- This federal Project Grant award of $869,478 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research into the cellular and molecular mechanisms underlying hereditary prion diseases. The awardee, Trustees of Boston University, is using cutting-edge induced pluripotent stem cell (iPSC) approaches to model and study Creutzfeldt-Jakob disease (CJD) pathology in...
- This Project Grant award, with a total funding amount of $909,090, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research aimed at developing a therapeutic strategy to treat prion diseases, a rare class of neurodegenerative disorders. Specifically, the grant will fund investigations into a small molecule compound, A5,...
- This federal Project Grant award of $429,000.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to investigate the pathogenic mechanisms underlying Creutzfeldt-Jakob disease (CJD), a rapidly progressive dementia. The award will support research at the University of Texas Health Science Center at Houston to: 1) explore the structural differences between pathogenic and...
- This $3,109,857 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of a human induced pluripotent stem cell (iPSC)-derived hippocampal assembloid model to study the interaction between interneurons, tau toxicity, and circuit-related neuronal dysfunction associated with genetic forms of dementia. The research...
- This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
- This $1,002,148 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research on the role of autophagy, a cellular process for clearing damaged organelles and inclusions, in neurodegeneration. The research aims to determine how levels of the lipid phosphatidylinositol 3-phosphate (PI(3)P) regulate autophagy in neurons, including...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....
- This federal Project Grant award of $386,650 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at Midwestern University in Glendale, Arizona to identify the molecular target and cellular mechanisms by which the novel compound elacridar exerts anti-prion effects. The research aims to further explore the potential application of elacridar to treat other...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
DETERMINING PATHOGENIC PRPC-INDUCED SIGNALING PATHWAYS IN HUMAN IPSC-INDUCED NEURONS - PRION DISEASES ARE RARE, INVARIABLY FATAL NEURODEGENERATIVE DISORDERS CHARACTERIZED BY RAPID COGNITIVE AND MOTOR DECLINE. CERTAIN PATHOLOGIC FEATURES OVERLAP WITH ALZHEIMER'S DISEASE, INCLUDING PROTEIN AGGREGATES AND MASSIVE SYNAPSE LOSS IN THE BRAIN, YET THE SEQUENCE OF EVENTS DRIVING SYNAPTIC LOSS IS INCOMPLETELY UNDERSTOOD. IN PRION AND ALZHEIMER'S DISEASE MODELS, NEURONAL CELLULAR PRION PROTEIN (PRPC) REPORTEDLY BINDS OLIGOMERS AND ELICITS A CASCADE OF INTRACELLULAR SIGNALS, WHEREAS PRPC DELETION AMELIORATES SYNAPTIC IMPAIRMENT, STRONGLY IMPLICATING NEURONAL PRPC IN ALTERING SIGNAL TRANSDUCTION EVENTS. USING UNBIASED TRANSCRIPTOMICS ON PRION- INFECTED MOUSE BRAIN, WE HAVE FOUND THAT IMMEDIATE EARLY GENES ARE AMONG THE EARLIEST, MOST SIGNIFICANTLY UPREGULATED GENES IN THE HIPPOCAMPUS, SUGGESTIVE OF HEIGHTENED NEURONAL ACTIVITY. WE HAVE ALSO DISCOVERED EARLY ABERRANT NEURONAL KINASE ACTIVITY IN THE HIPPOCAMPUS AND CORTEX. NOTABLY, SIMILAR KINASE MODIFICATIONS WERE INCITED IN HUMAN IPSC-INDUCED NEURONS WITHIN 2 HOURS OF TRIGGERING PRPC. IN AIM 1, WE WILL DETERMINE HOW AN ANTI-PRP ANTIBODY LIGAND OR PURIFIED INFECTIOUS PRION OLIGOMERS INDUCE SYNAPTIC KINASE SIGNALING IN HUMAN IPSC-INDUCED NEURONS. IN AIM 2, WE USE HIGHLY SENSITIVE AND QUANTITATIVE PROTEOMICS TO IDENTIFY THE PRPC- TRANSMEMBRANE SIGNALING NETWORK COMPONENTS AND NETWORK ALTERATIONS IN HUMAN NEURONS TRIGGERED BY A PRION PROTEIN LIGAND. THESE STUDIES ARE THE FIRST TO PURSUE PRPC-INITIATED SIGNALING PATHWAYS IN HUMAN NEURONS, AND ARE EXPECTED TO ESTABLISH THE SIGNALING PARAMETERS AND DOWNSTREAM CONSEQUENCES AS WELL AS PROVIDE INSIGHT INTO EVENTS LEADING TO SYNAPSE LOSS IN DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/18/25 | ||
| Not listed | $434.5k | 9/7/23 |